Just reported
From Resmed's results release of 29 oktober 2026; its quarterly report has since been filed.
Actual
US$ 1,41B
+5,9% y/y
-3,3% q/q
Guided
—
No guide given
Actual
US$ 2,92
+23% y/y
+11% q/q
Guided
—
No guide given
Actual
US$ 453M
+1,4% y/y
+1,0% q/q
Guided
—
No guide given
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
De omzetaandelen zijn schattingen voor quarter ended 2026-03-31, geen cijfers uit een ingediend rapport.
AirSense 11
A connected machine that delivers continuous or automatically adjusted air pressure to treat sleep apnea.
AirCurve 11
A bilevel breathing machine that provides different pressure levels for breathing in and out, for people needing more support or with complex breathing disorders.
Astral ventilators
Ventilators that provide breathing support, including for people receiving care at home.
AirTouch N30i, AirTouch F30i, and AirFit F40 masks
Masks that connect a person to a breathing machine during sleep; the named models include fabric and silicone designs.
myAir and AirView
Software for patients to engage with their sleep treatment and for providers to connect with and support patients.
Brightree and MEDIFOX DAN
Software products for residential care and home medical equipment providers.
ResMed makes devices that help people breathe during sleep and ventilators for people who need breathing support. It also sells masks and software for patients, medical equipment providers, and residential care providers. Its sleep products include machines that connect with patient and provider software.
Gebouwd uit de eigen deponeringen van Resmed Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
The themes Resmed is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$ 239,53+0,2%slot 13 nov
Cijfers tot en met 30 september 2026, uit de 10-Q ingediend op 30 oktober 2026
ResMed sells breathing machines and masks for sleep apnea and other breathing disorders to patients through medical equipment providers.
Grade B+
De balk onder de koers toont het cijfer op elke datum, alleen gebaseerd op de stukken die toen al openbaar waren.
Toont 2 van 41 kwartalen van de cijferhistorie van Resmed Inc.. De andere 39 lopen terug tot oktober 2016.
